There are currently 20 patients involved on the Clinical Trial.

t-PDA (trial patient aid)

The ImmunoSABR trial team has been working together with a young Belgian start-up, MedC2, to develop an app for potential participants. This trial Patient Decision Aid will support patients in taking an active part in discussion with their doctor about their participation in the ImmunoSABR trial. The app is currently being reviewed by the Ethical Committee of UMC+. Access to the app will be granted after the approval of the app by the ethical committee.

Publications

  • The scientific paper with the results of the phase 1 trial testing the combination of Immunocytokines  radiotherapy ”Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study “ is online (https://pubmed.ncbi.nlm.nih.gov/33285270/  or DOI: 10.1016/j.ijrobp.2020.11.053  ). A key sentence is “We documented 2 long-term progression-free responders (out of 6), both having non-small cell lung cancer as primary tumor.”
  • The paper describes the protocol “ Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial “ is online:
    https://pubmed.ncbi.nlm.nih.gov/32539805/

 

About the project:

​

https://youtu.be/fC_SWhxK-zU